Controversies in the management of alcoholic liver disease

Hui Hui Tan, Sharad Virmani, Paul Martin

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Alcohol is a risk factor for chronic disease burden in developed countries. Alcoholic liver disease affects 1% of the North American population and is the second most frequent indication for liver transplantation in the United States. It is a spectrum that ranges from simple hepatic steatosis to alcoholic hepatitis to steatohepatitis and eventually cirrhosis. The clinical spectrum of alcoholic hepatitis is wide and ranges from the asymptomatic patient to overt liver failure and death. Liver biopsy as a means of prognostication in alcoholic hepatitis has mostly been replaced with less invasive scoring systems. The management of alcoholic liver disease is challenging. Abstinence is the cornerstone of therapy and should include rehabilitation with a multidisciplinary approach. No specific treatment is required in mild to moderate alcoholic hepatitis. In patients with severe hepatitis, there appears to be a moderate survival benefit from the use of either corticosteroids or pentoxifylline in the absence of contraindications to their use. Non-responders should have steroid therapy withdrawn by day 7, as persistence with therapy is not beneficial. Orthotopic liver transplantation remains the definitive therapy for decompensated alcoholic cirrhosis despite alcohol abstinence. More studies are needed to define the optimal timing of orthotopic liver transplantation and patients at risk of alcohol relapse post-transplant.

Original languageEnglish
Pages (from-to)484-498
Number of pages15
JournalMount Sinai Journal of Medicine
Volume76
Issue number5
DOIs
StatePublished - Oct 1 2009

Fingerprint

Alcoholic Liver Diseases
Alcoholic Hepatitis
Liver Transplantation
Alcohols
Alcohol Abstinence
Therapeutics
Alcoholic Liver Cirrhosis
Pentoxifylline
Liver
Liver Failure
Fatty Liver
Developed Countries
Hepatitis
Adrenal Cortex Hormones
Fibrosis
Chronic Disease
Rehabilitation
Steroids
Transplants
Biopsy

Keywords

  • Alcohol abuse
  • Alcohol tolerance
  • Alcoholic hepatitis
  • Alcoholic liver disease
  • Liver transplant

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Controversies in the management of alcoholic liver disease. / Tan, Hui Hui; Virmani, Sharad; Martin, Paul.

In: Mount Sinai Journal of Medicine, Vol. 76, No. 5, 01.10.2009, p. 484-498.

Research output: Contribution to journalArticle

Tan, Hui Hui ; Virmani, Sharad ; Martin, Paul. / Controversies in the management of alcoholic liver disease. In: Mount Sinai Journal of Medicine. 2009 ; Vol. 76, No. 5. pp. 484-498.
@article{84d44e34cbdc4b9d8937b56696668506,
title = "Controversies in the management of alcoholic liver disease",
abstract = "Alcohol is a risk factor for chronic disease burden in developed countries. Alcoholic liver disease affects 1{\%} of the North American population and is the second most frequent indication for liver transplantation in the United States. It is a spectrum that ranges from simple hepatic steatosis to alcoholic hepatitis to steatohepatitis and eventually cirrhosis. The clinical spectrum of alcoholic hepatitis is wide and ranges from the asymptomatic patient to overt liver failure and death. Liver biopsy as a means of prognostication in alcoholic hepatitis has mostly been replaced with less invasive scoring systems. The management of alcoholic liver disease is challenging. Abstinence is the cornerstone of therapy and should include rehabilitation with a multidisciplinary approach. No specific treatment is required in mild to moderate alcoholic hepatitis. In patients with severe hepatitis, there appears to be a moderate survival benefit from the use of either corticosteroids or pentoxifylline in the absence of contraindications to their use. Non-responders should have steroid therapy withdrawn by day 7, as persistence with therapy is not beneficial. Orthotopic liver transplantation remains the definitive therapy for decompensated alcoholic cirrhosis despite alcohol abstinence. More studies are needed to define the optimal timing of orthotopic liver transplantation and patients at risk of alcohol relapse post-transplant.",
keywords = "Alcohol abuse, Alcohol tolerance, Alcoholic hepatitis, Alcoholic liver disease, Liver transplant",
author = "Tan, {Hui Hui} and Sharad Virmani and Paul Martin",
year = "2009",
month = "10",
day = "1",
doi = "10.1002/msj.20135",
language = "English",
volume = "76",
pages = "484--498",
journal = "Annals of Global Health",
issn = "2214-9996",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Controversies in the management of alcoholic liver disease

AU - Tan, Hui Hui

AU - Virmani, Sharad

AU - Martin, Paul

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Alcohol is a risk factor for chronic disease burden in developed countries. Alcoholic liver disease affects 1% of the North American population and is the second most frequent indication for liver transplantation in the United States. It is a spectrum that ranges from simple hepatic steatosis to alcoholic hepatitis to steatohepatitis and eventually cirrhosis. The clinical spectrum of alcoholic hepatitis is wide and ranges from the asymptomatic patient to overt liver failure and death. Liver biopsy as a means of prognostication in alcoholic hepatitis has mostly been replaced with less invasive scoring systems. The management of alcoholic liver disease is challenging. Abstinence is the cornerstone of therapy and should include rehabilitation with a multidisciplinary approach. No specific treatment is required in mild to moderate alcoholic hepatitis. In patients with severe hepatitis, there appears to be a moderate survival benefit from the use of either corticosteroids or pentoxifylline in the absence of contraindications to their use. Non-responders should have steroid therapy withdrawn by day 7, as persistence with therapy is not beneficial. Orthotopic liver transplantation remains the definitive therapy for decompensated alcoholic cirrhosis despite alcohol abstinence. More studies are needed to define the optimal timing of orthotopic liver transplantation and patients at risk of alcohol relapse post-transplant.

AB - Alcohol is a risk factor for chronic disease burden in developed countries. Alcoholic liver disease affects 1% of the North American population and is the second most frequent indication for liver transplantation in the United States. It is a spectrum that ranges from simple hepatic steatosis to alcoholic hepatitis to steatohepatitis and eventually cirrhosis. The clinical spectrum of alcoholic hepatitis is wide and ranges from the asymptomatic patient to overt liver failure and death. Liver biopsy as a means of prognostication in alcoholic hepatitis has mostly been replaced with less invasive scoring systems. The management of alcoholic liver disease is challenging. Abstinence is the cornerstone of therapy and should include rehabilitation with a multidisciplinary approach. No specific treatment is required in mild to moderate alcoholic hepatitis. In patients with severe hepatitis, there appears to be a moderate survival benefit from the use of either corticosteroids or pentoxifylline in the absence of contraindications to their use. Non-responders should have steroid therapy withdrawn by day 7, as persistence with therapy is not beneficial. Orthotopic liver transplantation remains the definitive therapy for decompensated alcoholic cirrhosis despite alcohol abstinence. More studies are needed to define the optimal timing of orthotopic liver transplantation and patients at risk of alcohol relapse post-transplant.

KW - Alcohol abuse

KW - Alcohol tolerance

KW - Alcoholic hepatitis

KW - Alcoholic liver disease

KW - Liver transplant

UR - http://www.scopus.com/inward/record.url?scp=70350719344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350719344&partnerID=8YFLogxK

U2 - 10.1002/msj.20135

DO - 10.1002/msj.20135

M3 - Article

C2 - 19787655

AN - SCOPUS:70350719344

VL - 76

SP - 484

EP - 498

JO - Annals of Global Health

JF - Annals of Global Health

SN - 2214-9996

IS - 5

ER -